['psoriatic arthritis']
['placebo', 'ixekizumab 80 mg q4w', 'ixekizumab 80 mg q2w']

        Inclusion Criteria:

          -  Presents with established diagnosis of active psoriatic arthritis (PsA) for at least 6
             months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria

          -  Active PsA defined as the presence of at least 3 tender and at least 3 swollen joints

          -  Presence of active psoriatic skin lesion or a history of plaque psoriasis (Ps)

          -  Men must agree to use a reliable method of birth control or remain abstinent during
             the study

          -  Women must agree to use reliable birth control or remain abstinent during the study
             and for at least 12 weeks after stopping treatment

          -  Have been treated with 1 or more conventional disease-modifying antirheumatic drugs
             (cDMARDs)

          -  Have had prior treatment with at least 1 and not more than 2 tumor necrosis factor
             (TNF) inhibitors. The participant must have discontinued at least 1 TNF inhibitor due
             to either an inadequate response (based on a minimum of 12 weeks on therapy) or
             documented intolerance.

        Exclusion Criteria:

          -  Current use of biologic agents for treatment of Ps or PsA

          -  Inadequate response to greater than 2 biologic DMARDs

          -  Current use of more than one cDMARDs

          -  Diagnosis of active inflammatory arthritic syndromes or spondyloarthropathies other
             than PsA

          -  Have received treatment with interleukin (IL) -17 or IL12/23 targeted monoclonal
             antibody (MAb) therapy

          -  Serious disorder or illness other than psoriatic arthritis

          -  Serious infection within the last 3 months

          -  Breastfeeding or nursing (lactating) women
      